(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 4.94% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of -0.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.57%.
Exagen's revenue in 2023 is $51,620,000.On average, 3 Wall Street analysts forecast XGN's revenue for 2023 to be $856,263,028, with the lowest XGN revenue forecast at $852,291,350, and the highest XGN revenue forecast at $860,814,264. On average, 3 Wall Street analysts forecast XGN's revenue for 2024 to be $942,054,675, with the lowest XGN revenue forecast at $927,292,989, and the highest XGN revenue forecast at $952,861,729.
In 2025, XGN is forecast to generate $1,135,252,078 in revenue, with the lowest revenue forecast at $1,135,252,078 and the highest revenue forecast at $1,135,252,078.